HALEON PLC with ticker (LON:HLN) now has a potential upside of 8.3% according to Barclays.
Barclays set a target price of 383 GBX for the company, which when compared to the HALEON PLC share price of 354 GBX at opening today (21/04/2023) indicates a potential upside of 8.3%. Trading has ranged between 241 (52 week low) and 356 (52 week high) with an average of 14,546,209 shares exchanging hands daily. The market capitalisation at the time of writing is £32,856,844,254.
Haleon plc is a consumer healthcare company. The Company’s product portfolio is divided among five categories: Oral Health; Pain Relief; vitamins, minerals and supplements (VMS); Respiratory Health; Digestive Health, and Other. Its portfolio of brands includes Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax and Centrum. In addition, the Company also has local strategic brands, which include TUMS, ENO, Flonase, ChapStick, Emergen-C, Fenbid, Grand-Pa, and Dr.BEST. The Company operates its business units in three regions: North America; Europe, Middle East, and Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC).
HALEON PLC 8.3% potential upside indicated by Barclays
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
Haleon plc has released its Annual Report for 2024, detailing vital financial information and upcoming AGM plans. Discover key insights for investors now.
Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights.
Haleon plc (NYSE/LON:HLN) impresses with solid Q1 results, showcasing organic revenue growth despite market challenges. Explore key sectors and financial highlights here. #Haleon #ConsumerHealth
Haleon plc appoints Dawn Allen as Chief Financial Officer, effective 28 October 2024. Tobias Hestler to step down due to health condition.
